98 related articles for article (PubMed ID: 9444606)
1. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Müller-Peddinghaus R
J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606
[TBL] [Abstract][Full Text] [Related]
2. FLAP inhibitors for the treatment of inflammatory diseases.
Sampson AP
Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784
[TBL] [Abstract][Full Text] [Related]
3. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Nickerson-Nutter CL; Medvedeff ED
Arthritis Rheum; 1996 Mar; 39(3):515-21. PubMed ID: 8607901
[TBL] [Abstract][Full Text] [Related]
4. Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test.
Burchardt ER; Müller-Peddinghaus R
Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):301-6. PubMed ID: 9150376
[TBL] [Abstract][Full Text] [Related]
5. Leukotrienes in respiratory disease.
McMillan RM
Paediatr Respir Rev; 2001 Sep; 2(3):238-44. PubMed ID: 12052325
[TBL] [Abstract][Full Text] [Related]
6. [Substances affecting the synthesis and activity of leukotrienes].
Opletalová V; Hartl J; Bĕhounková M
Ceska Slov Farm; 1997 Apr; 46(2):51-7. PubMed ID: 9244564
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
[TBL] [Abstract][Full Text] [Related]
8. Favorable combination effects of the leukotriene synthesis inhibitor BAY X 1005 and dexamethasone on edema formation in the arachidonic acid-induced mouse ear inflammation test.
Burchardt ER; Müller-Peddinghaus R
Prostaglandins Leukot Essent Fatty Acids; 1999 Jan; 60(1):5-11. PubMed ID: 10319912
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.
He W; Pelletier JP; Martel-Pelletier J; Laufer S; Di Battista JA
J Rheumatol; 2002 Mar; 29(3):546-53. PubMed ID: 11908571
[TBL] [Abstract][Full Text] [Related]
10. Lipoxygenase inhibition: the neglected frontier for regulating chronic inflammation and pain.
Whitehouse MW; Rainsford KD
Inflammopharmacology; 2006 Aug; 14(3-4):99-102. PubMed ID: 16983490
[No Abstract] [Full Text] [Related]
11. [The effects of cyclooxygenase and lipoxygenase inhibitors: the prerequisites for more effective anti-inflammatory combinations].
Vlaskovska M
Eksp Med Morfol; 1990; 29(1):44-53. PubMed ID: 2118852
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast.
Ramires R; Caiaffa MF; Tursi A; Haeggström JZ; Macchia L
Biochem Biophys Res Commun; 2004 Nov; 324(2):815-21. PubMed ID: 15474500
[TBL] [Abstract][Full Text] [Related]
13. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Kohlsdorfer C; Theisen-Popp P; Fruchtmann R; Perzborn E; Beckermann B; Bühner K; Ahr HJ; Mohrs KH
J Pharmacol Exp Ther; 1993 Oct; 267(1):51-7. PubMed ID: 8229782
[TBL] [Abstract][Full Text] [Related]
14. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
[TBL] [Abstract][Full Text] [Related]
15. Role of eicosanoids in inflammatory reactions of rats.
Hirschelmann R; Zarnack S; Funke T; Schmidt K; Bekemeier H; Giessler AJ; Ulbricht H
Biomed Biochim Acta; 1988; 47(10-11):S316-9. PubMed ID: 3150274
[TBL] [Abstract][Full Text] [Related]
16. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti-allergic and anti-inflammatory effects of drugs that inhibit lipoxygenase activity in vitro.
Etienne A; Soulard C; Touvay C; Clostre F; Braquet P
Int J Tissue React; 1985; 7(6):459-62. PubMed ID: 3936815
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
[TBL] [Abstract][Full Text] [Related]
20. Leukotrienes: lipid bioeffectors of inflammatory reactions.
Sala A; Zarini S; Bolla M
Biochemistry (Mosc); 1998 Jan; 63(1):84-92. PubMed ID: 9526099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
